To the Editor We read with interest the article by Wang et al1 in JAMA Surgery. We congratulate the authors on undertaking a large, randomized study in a unique population; however, we wanted to bring up some concerns regarding the study rationale and results.
First, the authors examined the morbidity and mortality of minimally invasive esophagectomy (MIE) after 2 neoadjuvant approaches in patients with esophageal squamous cell cancer (ESCC). They argue that both neoadjuvant chemotherapy and chemoradiation are reasonable preoperative options because the optimal regimen is not fully established. They defend this by stating that (1) only 3 trials have directly compared chemoradiation with chemotherapy and were mainly including patients with adenocarcinoma and (2) none were specifically done with MIE.
Trikalinos NA, Robinson CG, Park H. Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus. JAMA Surg. 2022;157(1):83–84. doi:10.1001/jamasurg.2021.4532
Surgery in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.